Chris Peetz is chief executive officer and board member of Mirum Pharmaceuticals, bringing deep experience in therapeutic development and commercialization. He also serves as an entrepreneur-in-residence at Frazier Healthcare Partners, focusing on liver diseases and related therapeutic areas.
Previously, he served as chief financial officer and head of corporate development at Tobira Therapeutics, a leading developer of therapeutics to treat non-alcoholic steatohepatitis (NASH). While at Tobira, he led the company’s efforts to become a public company through a reverse merger, expand its pipeline through partnerships and in-licensing, and sell the company to Allergan for up to $1.7 billion. Prior to Tobira, Chris held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix. Chris holds a Bachelor of Science in Business Administration from Washington University in St. Louis and an MBA from the Stanford Graduate School of Business.